REGN vs. VST
REGN (Regeneron Pharmaceuticals, Inc.) and VST (Vistra Corp.) are both stocks. REGN operates in Biotechnology (Healthcare), while VST operates in Utilities - Independent Power Producers (Utilities). Over the past 5 years, REGN returned 3.27%/yr vs 54.40%/yr for VST. At a 0.10 correlation, their price movements are largely independent.
Performance
REGN vs. VST - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, REGN achieves a -20.48% return, which is significantly lower than VST's -8.13% return.
REGN
- 1D
- 0.11%
- 1M
- -14.00%
- YTD
- -20.48%
- 6M
- -17.20%
- 1Y
- 16.30%
- 3Y*
- -7.00%
- 5Y*
- 3.27%
- 10Y*
- 5.35%
VST
- 1D
- 1.12%
- 1M
- 4.31%
- YTD
- -8.13%
- 6M
- -12.74%
- 1Y
- -14.37%
- 3Y*
- 83.39%
- 5Y*
- 54.40%
- 10Y*
- —
REGN vs. VST - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
REGN Regeneron Pharmaceuticals, Inc. | -20.48% | 8.96% | -18.90% | 21.73% | 14.25% | 30.72% | 28.66% | 0.53% | -0.65% | 2.42% |
VST Vistra Corp. | -8.13% | 17.66% | 261.52% | 70.73% | 5.08% | 19.57% | -11.87% | 2.46% | 24.95% | 18.19% |
Correlation
The correlation between REGN and VST is 0.02, meaning there is essentially no relationship between their price movements. Each responds to its own set of market drivers, making them strong candidates for combining in a diversified portfolio.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.02 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.04 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.11 |
Correlation (All Time) Calculated using the full available price history since Oct 4, 2016 | 0.10 |
Fundamentals
REGN:
$41.05
VST:
$8.60
REGN:
14.91
VST:
17.20
REGN:
4.42
VST:
2.19
REGN:
$14.92B
VST:
$17.20B
REGN:
$12.61B
VST:
$1.12B
REGN:
$5.74B
VST:
$4.34B
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
REGN vs. VST — Risk / Return Rank
REGN
VST
REGN vs. VST - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Regeneron Pharmaceuticals, Inc. (REGN) and Vistra Corp. (VST). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| REGN | VST | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +0.85 | ||
| Sortino ratioReturn per unit of downside risk | +1.10 | ||
| Omega ratioGain probability vs. loss probability | 1.12 | 0.99 | +0.14 |
| Calmar ratioReturn relative to maximum drawdown | 0.70 | -0.38 | +1.08 |
| Martin ratioReturn relative to average drawdown | 2.16 | -0.70 | +2.86 |
Loading charts...
Drawdowns
REGN vs. VST - Drawdown Comparison
The maximum REGN drawdown since its inception was -91.81%, which is greater than VST's maximum drawdown of -53.32%. Use the drawdown chart below to compare losses from any high point for REGN and VST.
Loading charts...
Drawdown Indicators
| REGN | VST | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -91.81% | -53.32% | -38.49% |
Max Drawdown (1Y)Largest decline over 1 year | -25.85% | -38.01% | +12.16% |
Max Drawdown (3Y)Largest decline over 3 years | -59.69% | -48.80% | -10.89% |
Max Drawdown (5Y)Largest decline over 5 years | -59.69% | -48.80% | -10.89% |
Max Drawdown (10Y)Largest decline over 10 years | -59.69% | — | — |
Current DrawdownCurrent decline from peak | -48.64% | -31.89% | -16.75% |
Average DrawdownAverage peak-to-trough decline | -42.45% | -13.72% | -28.73% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 8.33% | 20.73% | -12.40% |
Volatility
REGN vs. VST - Volatility Comparison
The current volatility for Regeneron Pharmaceuticals, Inc. (REGN) is 12.77%, while Vistra Corp. (VST) has a volatility of 15.14%. This indicates that REGN experiences smaller price fluctuations and is considered to be less risky than VST based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| REGN | VST | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 12.77% | 15.14% | -2.37% |
Volatility (6M)Calculated over the trailing 6-month period | 22.14% | 37.96% | -15.82% |
Volatility (1Y)Calculated over the trailing 1-year period | 32.77% | 48.75% | -15.98% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 30.79% | 47.97% | -17.18% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 32.17% | 42.22% | -10.05% |
Dividends
REGN vs. VST - Dividend Comparison
REGN's dividend yield for the trailing twelve months is around 0.59%, less than VST's 0.61% yield.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
REGN Regeneron Pharmaceuticals, Inc. | 0.59% | 0.46% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
VST Vistra Corp. | 0.61% | 0.56% | 0.63% | 2.13% | 3.12% | 2.64% | 2.75% | 2.17% | 0.00% | 0.00% | 14.97% |
Financials
REGN vs. VST - Financials Comparison
This section allows you to compare key financial metrics between Regeneron Pharmaceuticals, Inc. and Vistra Corp.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
REGN vs. VST - Profitability Comparison
REGN - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Regeneron Pharmaceuticals, Inc. reported a gross profit of 2.94B and revenue of 3.61B. Therefore, the gross margin over that period was 81.4%.
VST - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Vistra Corp. reported a gross profit of 0.00 and revenue of 5.64B. Therefore, the gross margin over that period was 0.0%.
REGN - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Regeneron Pharmaceuticals, Inc. reported an operating income of 642.90M and revenue of 3.61B, resulting in an operating margin of 17.8%.
VST - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Vistra Corp. reported an operating income of 1.50B and revenue of 5.64B, resulting in an operating margin of 26.6%.
REGN - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Regeneron Pharmaceuticals, Inc. reported a net income of 727.20M and revenue of 3.61B, resulting in a net margin of 20.2%.
VST - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Vistra Corp. reported a net income of 980.00M and revenue of 5.64B, resulting in a net margin of 17.4%.
Frequently Asked Questions
REGN and VST have a correlation of 0.02, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
VST has higher volatility (15.14%) compared to REGN (12.77%). In terms of maximum drawdown, REGN dropped -91.81% vs VST's -53.32%.
REGN currently has the higher Sharpe Ratio (0.55 vs -0.30), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for REGN and VST
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer